We agree with Parr et al. that our finding of linkage to 21q in relative pairs affected with autism and regression needs to be replicated. However, it is our hypothesis that regression represents a modification of disease presentation that may not be present in all relatives affected by autism. The goal of our study was to identify markers that segregated with regression. Thus, it was important to examine only those pairs concordant for regression. In this study, Parr and colleagues examined 86 autism affected relative pairs in which at least one had a history of regression, but only 12 of those pairs were concordant. They found no evidence of linkage, and this concurs with our analysis of the larger AGRE data set of affected relative pairs in which one or both had a history of regression (n = 136). Defining the phenotype as autism in this group, we found only nominal evidence of linkage on chromosome 21. It is our hope that the large consortiums for genetic studies of autism will accrue large enough samples to conduct an analysis of affected relative pairs concordant for autism and regression that would replicate our study.
The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autoreceptor inhibition An extremely important therapeutic advantage of atypical antipsychotic drugs, such as clozapine and olanzapine, is improvement of cognitive function in schizophrenia. It is now acknowledged that trait memory/executive deficits comprise a core and particularly debilitating cluster of symptoms in the semiology of schizophrenia and represent a vital unmet medical need.
Acetylcholinesterase inhibitors and procholinergic drugs can improve memory in Alzheimer's disease and other cognitive disorders.
1,2 Interestingly, the procognitive effects of olanzapine and clozapine have been associated with their ability to elevate extracellular acetylcholine concentrations in cortical regions. Thus, olanzapine and clozapine, but not typical antipsychotic drugs, markedly increase acetylcholine in the rat prefrontal cortex 3 and hippocampus 4 through a still unidentified mechanism. It was recently proposed that olanzapine and clozapine might increase acetylcholine release by blocking muscarinic autoreceptors. 5 First, olanzapine was shown to bind to muscarinic receptors, of the M2 subtype preferentially, in the human brain. 6 Second, in a number of in vitro studies, olanzapine and clozapine display a muscarinic receptor antagonist profile. Muscarinic receptor antagonists, such as scopolamine, increase acetylcholine release by disrupting muscarinic autoreceptor-mediated autoinhibition.
However, even in vitro, the potential contribution of the interaction of clozapine and olanzapine with muscarinic receptors on the efficacy of the compounds in vivo remains contentious. Besides, scopolamine, as well as genetic invalidation of muscarinic autoreceptors 7, 8 result in a profound impairment of cognitive function. In addition, muscarinic autoreceptor agonists rather than antagonists could help not only to control psychotic symptoms 9 but also to invoke functional, whole-spectrum recovery in schizophrenia.
M2 and M4 receptors constitute the main hippocampal acetylcholine autoreceptors. 7 M3 receptors, which set impulse-flow in the septohippocampal pathway, could also regulate cortical/hippocampal acetylcholine release. Establishing whether muscarinic receptor antagonist activity mediates the procholinergic effects of atypical antipsychotic drugs in the hippocampus is of high significance, as memory/ executive functions are crucial targets in the development of newer antipsychotic medications.
Accordingly, we assessed the effects of systemic administration of olanzapine (3 mg/kg intraperitoneally (i.p.), a fully efficacious dose in rodents) on hippocampal acetylcholine efflux in M2/M4 and M3 receptor knockout mice and their wild-type littermates, by in vivo microdialysis. As a positive control, we also assessed the effects of systemic administration of scopolamine (0.3 mg/kg i.p., a memory-impairing dose in rodents) under the same conditions. M2/M4 and M3 receptor knockout mice, generated as previously described, 7, 10 and respective wild-type mice were implanted in the hippocampus with microdialysis probes. Surgical procedures, microdialysis experiments and determination of acetylcholine in hippocampal dialysates were conducted as detailed before. 7 Data were analyzed with three-way (genotype Â treatment Â time) analysis of variance (ANOVA) followed by two-or one-way ANOVA and Duncan's test. Basal acetylcholine levels were markedly increased in the hippocampus of M2/M4 receptor knockout mice, 670718 fmol/15 min, compared to the wild-type mice, 18076 fmol/15 min, in concert with previous findings. 7 There was no difference in basal hippocampal acetylcholine levels between M3 receptor knockout (249764 fmol/15 min) and wild-type (228783 fmol/15 min) mice.
As compared to vehicle injection, olanzapine significantly increased acetylcholine efflux in the hippocampus of both M2/M4 receptor wild-type and knockout mice (Figure 1a) . Similarly, olanzapine, compared to vehicle, significantly increased acetylcholine efflux in the hippocampus of both M3 receptor wild-type and knockout mice (Figure 1b) . In all genotypes, acetylcholine was increased, up to a peak value of 280%, 15 min after the injection of olanzapine and remained elevated throughout the 2 h observation period. In contrast, the acetylcholinereleasing properties of scopolamine were abolished in M2/M4 receptor knockout mice (Figure 1c ), in accordance with the predominant autoreceptor role of these inhibitory Gi/Go-coupled receptors. In the M3 receptor knockout mice, the effects of scopolamine . Scopolamine-induced acetylcholine release is reduced in knockout mice (F 1,11 = 2.25 P < 0.05 for M2/M4; F 1,9 = 11.9 P < 0.05 for M3). Data (expressed as fold over baseline established before any treatment) represent mean7s.e.m. of n = 4-6 animals per group. *P < 0.05 as compared to the respective wild-type group.
were also reduced in a statistically significant manner (Figure 1d ). We demonstrated that the procholinergic effects of olanzapine do not seem to involve M2, M3 or M4 muscarinic receptor antagonism, as its effects were retained in animals in which these receptors were genetically invalidated. In contrast, the muscarinic receptor antagonist scopolamine appears to increase acetylcholine release by muscarinic autoreceptor disinhibition, as its effects were diminished in M2/ M4 and M3 muscarinic receptor knockout mice. Our findings imply that antimuscarinic activity is not required for the procholinergic, and possibly the procognitive effects of olanzapine. These results could be of particular significance for the rational strategic design of novel antipsychotic drugs. 
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